MA
SRNE

MYDA Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

MYDA Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,000
Closed -$48K – 152
2019
Q1 		$48K Buy
+10,000
New +$26.2K 0.02% 111
2018
Q3 		– Sell
-35,000
Closed -$252K – 195
2018
Q2 		$252K Buy
+35,000
New +$238K 0.11% 114
2018
Q1 		– Sell
-30,000
Closed -$114K – 199
2017
Q4 		$114K Buy
+30,000
New +$78.1K 0.05% 140

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

MYDA Advisors's SRNE Position: Q2 2019 in Review

MYDA Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2019, closing a stake of 10,000 shares — an estimated $48K sold.

MYDA Advisors first reported a position in SRNE in Q4 2017 and held it in 3 quarters. The position peaked at $252K in Q2 2018. 83 funds tracked by Wall St. Rank hold SRNE as of Q2 2019.

  • MYDA Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • MYDA Advisors sold 10,000 Sorrento Therapeutics, Inc. shares in Q2 2019, an estimated $48K.
  • MYDA Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 3 quarters.
  • MYDA Advisors's Sorrento Therapeutics, Inc. position peaked at $252K in Q2 2018.
  • 83 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2019.

Based on MYDA Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.